K. Nolop

发表

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

A. Hauschild, D. Schadendorf, K. Flaherty, 2011, The New England journal of medicine.

Vemurafenib: the first drug approved for BRAF-mutant cancer

P. Hirth, K. Nolop, G. Bollag, 2012, Nature Reviews Drug Discovery.

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

P. Gibbs, J. Desai, J. Issa, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of mutated, activated BRAF in metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2010, The New England journal of medicine.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Kam Y. J. Zhang, K. Flaherty, J. Sosman, 2010, Nature.

Glucose utilization in vivo by human pulmonary neoplasms

T Jones, R. Beaney, C. Rhodes, 1987, Cancer.

Comparison of lung vascular and epithelial permeability indices in the adult respiratory distress syndrome.

P. Barnes, K. Nolop, D. Royston, 2015, The American review of respiratory disease.

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

Kam Y. J. Zhang, G. Habets, P. Hirth, 2013, Proceedings of the National Academy of Sciences.

Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM).

K. Flaherty, J. Sosman, A. Ribas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma .

A. Hauschild, K. Flaherty, P. Ascierto, 2012 .

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.

J. Kemp, J. Murray, K. Nolop, 2000, The Journal of allergy and clinical immunology.

Somatostatin inhibits the ventilatory response to hypoxia in humans.

K. Nolop, D. Maxwell, J. Hughes, 1986, Journal of applied physiology.

A Comparison of Double-Strength Beclomethasone Dipropionate (84 μg) MDI With Beclomethasone Dipropionate (42 μ) MDI in the Treatment of Asthma

R. Nathan, K. Nolop, F. Cuss, 1997 .

A comparison of double-strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma.

R. Nathan, K. Nolop, F. Cuss, 1997, Chest.

Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma.

D. Webb, D. Bernstein, R. Nathan, 2000, The Journal of allergy and clinical immunology.

MR imaging parameters in the study of lung water. A preliminary study.

K. Nolop, J. Loyd, F. Carroll, 1985, Investigative radiology.

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.

Richard J. Lee, A. Lazar, Michelle D. Williams, 2013, Thyroid : official journal of the American Thyroid Association.

Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.

A. Hauschild, D. Schadendorf, K. Flaherty, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Positive end-expiratory pressure increases pulmonary clearance of inhaled 99mTc-DTPA in nonsmokers but not in healthy smokers.

K. Nolop, D. Maxwell, D. Royston, 1987, Bulletin europeen de physiopathologie respiratoire.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Failure of aerosolised 99mTc DTPA clearance to predict outcome in patients with adult respiratory distress syndrome.

K. Nolop, D. Royston, S. Braude, 1987, Thorax.

Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray.

K. Nolop, S. Miller, David Skoner, 2000, Pediatrics.

Assessment by Nasal Biopsy of Long-Term Use of Mometasone Furoate Aqueous Nasal Spray (Nasonex) in the Treatment of Perennial Rhinitis

S. Durham, V. Lund, K. Nolop, 1998, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray.

K. Nolop, H. Kaiser, M. Vandewalker, 1996, The Journal of allergy and clinical immunology.

Once‐daily mometasone furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an active‐ and placebo‐controlled study

K. Nolop, J. Hébert, B. Lutsky, 1996, Allergy.

Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients.

William H. Yang, P. Van cauwenberge, K. Nolop, 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis.

K. Nolop, M. Zitt, M. Frieri, 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate.

T. Ahmed, R. Nathan, K. Nolop, 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group.

K. Nolop, B. Lutsky, M. Mandl, 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis.

R. Nathan, K. Nolop, R. Berkowitz, 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Once-daily rnornetasone furoate aqueous rhinitis: an active- and placebo-controlled

K. Nolop, J. Hébert, N. Lutsky, 1996 .

Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler.

G. Settipane, J. Kemp, D. Bernstein, 1999, Respiratory medicine.

Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler.

L. Boulet, J. Bousquet, K. Nolop, 2000, The European respiratory journal.

Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler1

L. Boulet, J. Bousquet, K. Nolop, 2022 .

The Responsiveness of Disease-Specific and Generic Health Measures to Changes in the Severity of Asthma Among Adults

J. Kemp, J. Ware, T. Goss, 1998, Quality of Life Research.

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma

A. Hauschild, K. Flaherty, P. Ascierto, 2011 .

A comparison of 99mTc-DTPA and 113mIn-DTPA aerosol clearances in humans. Effects of smoking, hyperinflation, and in vitro oxidation.

K. Nolop, D. Maxwell, J. Fleming, 1987, The American review of respiratory disease.

Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2010 .

Enhancement of tumor necrosis factor-induced endothelial cell injury by cycloheximide.

K. Nolop, U. Ryan, 1990, The American journal of physiology.

Endothelin‐1 from Pulmonary Artery and Micro vessels Acts on Vascular and Airway Smooth Muscle

K. Nolop, M. Glassberg, U. Ryan, 1989, Journal of Cardiovascular Pharmacology.

Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma.

K. Nolop, W. Lumry, A. Scardella, 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Effects of inspiratory resistance loading on lung fluid balance in awake sheep.

K. Nolop, J. Loyd, R. Roselli, 1986, Journal of applied physiology.

Effects of adenosine on ventilatory responses to hypoxia and hypercapnia in humans.

K. Nolop, D. Maxwell, R. Fuller, 1986, Journal of applied physiology.

Unprecedented sedative requirements during delirium tremens.

K. Nolop, A. Natow, 1985, Critical care medicine.

A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis.

R. Dockhorn, E. Meltzer, K. Nolop, 1999, The Journal of allergy and clinical immunology.

Microvascular and macrovascular endothelial cells produce different constrictor substances.

A. Wanner, K. Nolop, M. Glassberg, 1992, Journal of applied physiology.

Increased pulmonary transvascular protein flux after canine cardiopulmonary bypass. Association with lung neutrophil sequestration and tissue peroxidation.

K. Nolop, J. Fleming, T. Krausz, 1986, The American review of respiratory disease.

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

M. Prados, P. Wen, K. Ligon, 2016, Neuro-oncology.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Yu Shyr, Fei Ye, Donald Lawrence, 2012, The New England journal of medicine.

Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

A. Hauschild, D. Schadendorf, M. Lacouture, 2013, The oncologist.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

K. Flaherty, J. Reis-Filho, Qiongqing Wang, 2012, The New England journal of medicine.

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3.

A. Hauschild, K. Flaherty, P. Ascierto, 2011 .

PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

J. Desai, L. Saltz, S. Kopetz, 2010 .

Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation

R. Jorissen, P. Gibbs, M. Christie, 2011, International journal of cancer.

RAF inhibitors that evade paradoxical MAPK pathway activation

James Tsai, Ying Zhang, Paul S. Lin, 2015, Nature.

Effect of raised thoracic pressure and volume on 99mTc-DTPA clearance in humans.

K. Nolop, D. Maxwell, D. Royston, 1986, Journal of applied physiology.

Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer.

K. Flaherty, J. Sosman, R. J. Lee, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.

K. Flaherty, J. Sosman, A. Ribas, 2015, European journal of cancer.

PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial.

K. Flaherty, J. Sosman, A. Ribas, 2010 .

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6BA Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032

K. Flaherty, J. Sosman, A. Ribas, 2009 .

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

Shenghua Shi, Kam Y. J. Zhang, Sarah Will, 2009, Proceedings of the National Academy of Sciences.

Assessment by Nasal Biopsy of Long-Term Use of Mometasone Furoate Aqueous Nasal Spray (Nasonex) in the Treatment of Perennial Rhinitis:

S. Durham, V. Lund, K. Nolop, 1998 .

1004 Once daily mometasone furoate aqueous nasal spray in seasonal allergic rhinitis: An active and placebo-controlled study

K. Nolop, J. Hébert, B. Lutsky, 1996 .

Epithelial and endothelial flux after bypass in dogs: effect of positive end-expiratory pressure.

K. Nolop, D. Royston, K. Taylor, 1987, Journal of applied physiology.

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

R. Bociek, R. Gascoyne, L. Gordon, 2012 .

Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial

A. Hauschild, D. Schadendorf, K. Flaherty, 2011 .

Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.

D. Webb, J. Ramsdell, K. Nolop, 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.

I. Puzanov, D. V. Von Hoff, K. Nolop, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group.

K. Nolop, B. Lutsky, M. Mandl, 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial

A. Hauschild, K. Flaherty, P. Ascierto, 2011 .

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.

A. Hauschild, K. Flaherty, P. Ascierto, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selecting subjects for a therapeutic target in colorectal cancer (CRC): Using a clinical database to enrich for patients harboring the BRAFV600E mutation.

R. Jorissen, P. Gibbs, L. Lipton, 2009, Journal of Clinical Oncology.

Effects of somatostatin, naloxone and prochlorperazine on the control of ventilation in man.

K. Nolop, D. Maxwell, J. Hughes, 1986, Clinical science.

Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation

R. Jorissen, P. Gibbs, M. Christie, 2011, International journal of cancer.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Preclinical development of a novel inhibitor of oncogenic B-Raf.

P. Hirth, K. Nolop, G. Bollag, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.